Back

Clinical implications for post-ACS patients

27 August 2018 (18:55 - 19:10)
Organised by:
Congress Presentation Part of: Identifying patients who may benefit most from PCSK9i: highlights from the latest ODYSSEY OUTCOMES data Treatment Open Access ESC Congress 2018

About the speaker

Photo
Doctor Shaun Goodman

St. Michael's Hospital, Toronto (Canada)

6 More presentations in this session

Presentation thumbnail
Welcome and introduction - Highlights from the latest ODYSSEY OUTCOMES data
Professor A. Zeiher (Frankfurt, DE)
Slides Video
Presentation thumbnail
Learnings from the latest PCSK9i results and profiles of patients who may benefit the most: post- ACS patients with elevated atherogenic lipid levels
Professor P. Steg (Paris, FR)
Slides Video
Presentation thumbnail
Learnings from the latest PCSK9i results and and profiles of patients who may benefit the most: efficacy and safety of alirocumab in ODYSSEY OUTCOMES patients with diabetes
Professor K. Ray (London, GB)
Slides Video
Presentation thumbnail
Learnings from the latest PCSK9i results and profiles of patients who may benefit the most: a comprehensive review of the latest lipid lowering therapies outcomes data
Professor C. Cannon (Boston, US)
Slides Video
Presentation thumbnail
Roundtable: learnings in practice
Professor P. Steg (Paris, FR) Professor A. Zeiher (Frankfurt, DE)
Slides Video

Access the full session

Session thumbnail
Identifying patients who may benefit most from PCSK9i: highlights from the latest ODYSSEY OUTCOMES data

The Event

Event poster

ESC Congress 2018

27 August 2018 18:55 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources